Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|---|
Gross Sales | 1,551.37 | 1,369.73 | 1,420.91 | 1,412.82 | 1,361.62 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 1,551.37 | 1,369.73 | 1,420.91 | 1,412.82 | 1,361.62 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 14.69 | 10.96 | 6.39 | 10.85 | 8.36 |
Total Income | 1,566.06 | 1,380.69 | 1,427.3 | 1,423.66 | 1,369.98 |
Total Expenditure | 1,394.55 | 1,325.71 | 1,473.75 | 1,303.42 | 1,158.37 |
PBIDT | 171.51 | 54.98 | -46.45 | 120.25 | 211.61 |
Interest | 60.75 | 48.09 | 35.52 | 15.77 | 24.38 |
PBDT | 110.76 | 6.89 | -81.97 | 104.47 | 187.23 |
Depreciation | 66.45 | 61.54 | 55.69 | 51.54 | 50.6 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 40.89 | 13.95 | 7.52 | 13.7 | 35.04 |
Deferred Tax | -28.84 | -38.98 | -23.2 | -5.53 | -2.86 |
Reported Profit After Tax | 32.26 | -29.62 | -121.98 | 44.76 | 104.45 |
Minority Interest After NP | 10.38 | 6.26 | -0.82 | 3.81 | 9.01 |
Net Profit after Minority Interest | 21.88 | -35.88 | -121.16 | 40.96 | 95.44 |
Extra-ordinary Items | -0.38 | -12.95 | -61.26 | 0 | -6.56 |
Adjusted Profit After Extra-ordinary item | 22.26 | -22.93 | -59.9 | 40.96 | 102 |
EPS (Unit Curr.) | 0.88 | -1.44 | -4.88 | 1.65 | 3.87 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 25 |
Equity | 50.06 | 49.89 | 49.89 | 49.67 | 49.67 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 11.05 | 4.01 | -3.26 | 8.51 | 15.54 |
PBDTM(%) | 7.13 | 0.5 | -5.76 | 7.39 | 13.75 |
PATM(%) | 2.07 | -2.16 | -8.58 | 3.16 | 7.67 |
Viyash manufactures active pharmaceutical ingredients (APIs) and drug formulations for the human health segment.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.